INTRODUCTION: In severe spontaneous intraventricular hemorrhage (IVH), intraventricular (IVR) administration of tissue plasminogen activator (rtPA) clears blood from the ventricles more rapidly than with external ventricular drainage (EVD) alone. However, experimental studies suggest tPA may be neurotoxic in compromised brain tissue and may exacerbate perihematomal edema. METHODS: We used computerized volumetrics to assess change in intracerebral hemorrhage (ICH), IVH, ventricular, and perihematomal edema (PHE) volumes at 2-4 (T1) and 5-9 (T2) days following diagnostic CT scans (T0) of 24 patients (12 tPA-treated; 12 controls) with IVH requiring EVD. Controls from a hospital registry were matched by IVH and ICH volume to tPA-treated patients who came from a multicenter trial involving 52 patients with IVH. RESULTS: There were no significant differences between matched pairs in admission ICH and IVH volumes. IVR tPA resulted in more rapid clearance of IVH as determined by T2-T0 decrease in median IVH volume (tPA: -18.7 cc, iqr 14.9; control:-6.9 cc, iqr 6.4; P = 0.002). Median ratios of PHE to ICH volume were not significantly different in control versus tPA-treated patients at T1 and T2 [control:tPA = 0.55:0.56 (T1); P = 0.84 and 0.81:0.71 (T2); P = 1.00]. Total ventricular volume was significantly larger in the control group at T2 (mean: 57.57 ± 10.32 vs. tPA: 24.80 ± 2.67 cc; P = 0.01). Bacterial ventriculitis was more frequent in the control group (5 vs. 1 episodes; P = 0.06) as was shunt dependence (4 vs. 0 cases; P = 0.03). CONCLUSIONS: For case matched large IVH with small ICH volume, IVR tPA enhances lysis of intraventricular blood clots and has no significant impact on PHE.
INTRODUCTION: In severe spontaneous intraventricular hemorrhage (IVH), intraventricular (IVR) administration of tissue plasminogen activator (rtPA) clears blood from the ventricles more rapidly than with external ventricular drainage (EVD) alone. However, experimental studies suggest tPA may be neurotoxic in compromised brain tissue and may exacerbate perihematomal edema. METHODS: We used computerized volumetrics to assess change in intracerebral hemorrhage (ICH), IVH, ventricular, and perihematomal edema (PHE) volumes at 2-4 (T1) and 5-9 (T2) days following diagnostic CT scans (T0) of 24 patients (12 tPA-treated; 12 controls) with IVH requiring EVD. Controls from a hospital registry were matched by IVH and ICH volume to tPA-treated patients who came from a multicenter trial involving 52 patients with IVH. RESULTS: There were no significant differences between matched pairs in admission ICH and IVH volumes. IVR tPA resulted in more rapid clearance of IVH as determined by T2-T0 decrease in median IVH volume (tPA: -18.7 cc, iqr 14.9; control:-6.9 cc, iqr 6.4; P = 0.002). Median ratios of PHE to ICH volume were not significantly different in control versus tPA-treated patients at T1 and T2 [control:tPA = 0.55:0.56 (T1); P = 0.84 and 0.81:0.71 (T2); P = 1.00]. Total ventricular volume was significantly larger in the control group at T2 (mean: 57.57 ± 10.32 vs. tPA: 24.80 ± 2.67 cc; P = 0.01). Bacterial ventriculitis was more frequent in the control group (5 vs. 1 episodes; P = 0.06) as was shunt dependence (4 vs. 0 cases; P = 0.03). CONCLUSIONS: For case matched large IVH with small ICH volume, IVR tPA enhances lysis of intraventricular blood clots and has no significant impact on PHE.
Authors: H Arima; J G Wang; Y Huang; E Heeley; C Skulina; M W Parsons; B Peng; Q Li; S Su; Q L Tao; Y C Li; J D Jiang; L W Tai; J L Zhang; E Xu; Y Cheng; L B Morgenstern; J Chalmers; C S Anderson Journal: Neurology Date: 2009-12-08 Impact factor: 9.910
Authors: Lewis B Morgenstern; J Claude Hemphill; Craig Anderson; Kyra Becker; Joseph P Broderick; E Sander Connolly; Steven M Greenberg; James N Huang; R Loch MacDonald; Steven R Messé; Pamela H Mitchell; Magdy Selim; Rafael J Tamargo Journal: Stroke Date: 2010-07-22 Impact factor: 7.914
Authors: H B Huttner; E Tognoni; J Bardutzky; M Hartmann; M Köhrmann; I-C Kanter; E Jüttler; P D Schellinger; S Schwab Journal: Eur J Neurol Date: 2008-02-26 Impact factor: 6.089
Authors: Andreas H Kramer; Craig N Jenne; David A Zygun; Derek J Roberts; Michael D Hill; Jessalyn K Holodinsky; Stephanie Todd; Paul Kubes; John H Wong Journal: J Cereb Blood Flow Metab Date: 2015-04-08 Impact factor: 6.200
Authors: Audrey Leasure; W Taylor Kimberly; Lauren H Sansing; Kristopher T Kahle; Golo Kronenberg; Hagen Kunte; J Marc Simard; Kevin N Sheth Journal: Curr Treat Options Neurol Date: 2016-02 Impact factor: 3.598
Authors: Joji B Kuramatsu; Stefan T Gerner; Wendy Ziai; Stefan Schwab; Daniel F Hanley; Hagen B Huttner; Jürgen Bardutzky; Jochen A Sembill; Maximilian I Sprügel; Anne Mrochen; Kathrin Kölbl; Malathi Ram; Radhika Avadhani; Guido J Falcone; Magdy H Selim; Vasileios-Arsenios Lioutas; Matthias Endres; Sarah Zweynert; Peter Vajkoczy; Peter A Ringleb; Jan C Purrucker; Jens Volkmann; Hermann Neugebauer; Frank Erbguth; Peter D Schellinger; Ulrich J Knappe; Gereon R Fink; Christian Dohmen; Jens Minnerup; Heinz Reichmann; Hauke Schneider; Joachim Röther; Gernot Reimann; Michael Schwarz; Hansjörg Bäzner; Joseph Claßen; Dominik Michalski; Otto W Witte; Albrecht Günther; Gerhard F Hamann; Hannes Lücking; Arnd Dörfler; Muhammad Fawad Ishfaq; Jason J Chang; Fernando D Testai; Daniel Woo; Andrei V Alexandrov; Dimitre Staykov; Nitin Goyal; Georgios Tsivgoulis; Kevin N Sheth; Issam A Awad Journal: Stroke Date: 2022-05-06 Impact factor: 10.170